Study suggests a path forward for device therapy, though caveats are plenty ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

A head-to-head, randomized study of the two leading heart implants worldwide for reducing the risk of stroke among people with an irregular pulse found there was little difference between their safety ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

The Heart Institute of East Texas proudly introduces the latest advancement in cardiac care with the implementation of the Watchman Flx Pro Left Atrial Appendage Occluder implantation technology. This ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

The Amplatzer Amulet left atrial appendage (LAA) occluder was at least as good as the first-generation Watchman in keeping strokes down, according to the randomized IDE trial that helped convince FDA ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — At 3 years, the Amplatzer Amulet device ...

The newer-generation Watchman device was associated with sustained safety and efficacy out to 2 years when implanted in people at high thromboembolic risk, the PINNACLE FLX IDE study group reported.

VIENNA, AUSTRIA — Thrombi were sometimes found on two left-atrial-appendage (LAA) occluder devices in the weeks following implantation in two large registry studies of patients with atrial ...